Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Otonomy, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Otonomy, Inc. - Product Pipeline Review - 2014', provides an overview of the Otonomy, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Otonomy, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Otonomy, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Otonomy, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Otonomy, Inc.'s pipeline products Reasons to buy - Evaluate Otonomy, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Otonomy, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Otonomy, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Otonomy, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Otonomy, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Otonomy, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Otonomy, Inc. Snapshot 4 Otonomy, Inc. Overview 4 Key Information 4 Key Facts 4 Otonomy, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Otonomy, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Otonomy, Inc. - Pipeline Products Glance 9 Otonomy, Inc. - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Otonomy, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Otonomy, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Otonomy, Inc. - Drug Profiles 12 ciprofloxacin SR 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 dexamethasone acetate SR 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 gacyclidine 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Otonomy, Inc. - Pipeline Analysis 17 Otonomy, Inc. - Pipeline Products by Target 17 Otonomy, Inc. - Pipeline Products by Route of Administration 18 Otonomy, Inc. - Pipeline Products by Molecule Type 19 Otonomy, Inc. - Pipeline Products by Mechanism of Action 20 Otonomy, Inc. - Recent Pipeline Updates 21 Otonomy, Inc. - Locations And Subsidiaries 24 Head Office 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables Otonomy, Inc., Key Information 4 Otonomy, Inc., Key Facts 4 Otonomy, Inc. - Pipeline by Indication, 2014 6 Otonomy, Inc. - Pipeline by Stage of Development, 2014 7 Otonomy, Inc. - Monotherapy Products in Pipeline, 2014 8 Otonomy, Inc. - Phase III, 2014 9 Otonomy, Inc. - Phase II, 2014 10 Otonomy, Inc. - Preclinical, 2014 11 Otonomy, Inc. - Pipeline by Target, 2014 17 Otonomy, Inc. - Pipeline by Route of Administration, 2014 18 Otonomy, Inc. - Pipeline by Molecule Type, 2014 19 Otonomy, Inc. - Pipeline Products by Mechanism of Action, 2014 20 Otonomy, Inc. - Recent Pipeline Updates, 2014 21
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.